Drug delivery systems for potential treatment of intracellular bacterial infections

Imbuluzqueta, Edurne; Gamazo, Carlos; Ariza, Javier; Blanco-Prieto, María J.

doi:10.2741/3627

Cited by 81 publications

(60 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mine & Nolan (2004) also reported that heLDL could modulate immunity and promote the growth of human U937 monocyte-like cells and U937-derived macrophage-like cells (Frostegard et al, 1990;Mine & Nolan, 2004). Staphylococcus aureus could easily invade professional phagocytes and persists in the acidic lysosome compartment for several days (Imbuluzqueta et al, 2010). Rifapentine and rifampin, which show enforced bactericidal activity in acidic conditions, have been applied extensively in combinational antimicrobial therapies against intracellular S. aureus infections (Forrest & Tamura, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…These systems could be used not only to promote the delivery of therapeutic agents but also to increase the penetration of these materials into macrophages (Couvreur et al, 1991;Imbuluzqueta et al, 2010). There are, however, concerns surrounding the practical application of these drug delivery systems, including their stability, biocompatibility and immunogenicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Using rifapentine – hen egg lipoprotein conjugate as macrophage-targeted drug delivery carrier against intracellularStaphylococcus aureus

Yang

Liu

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

Context: Hen egg low-density lipoprotein (heLDL), which is present in large quantities in egg yolk, share a high identity with human apolipoprotein B-100 precursor.Objective: This study investigated the use of heLDL as a macrophage-targeted drug delivery carrier against intracellular Staphylococcus aureus. Methods: Rifapentine (RPT) was incorporated into heLDL (RPT-heLDL). Staphylococcus aureus ATCC 29740 and human U937 macrophage were used as intracellular infection models. Results and conclusion: The loading efficiency of RPT into the heLDL was 66.10 ± 2.28 mg RPT/mg heLDL. Fluorescence microscopy and oil red O staining results indicated RPT-heLDL can be taken up by U937 macrophages. The cell viability (MTT assay) was increased when the concentration of heLDL was 5150 mg/mL. Unloaded heLDL (100 mg/mL) can inhibit the growth of intracellular S. aureus compared with the untreated control group after 18 h incubation. RPT-heLDL (6.6 mg/mL RPT, 100 mg/mL heLDL) eliminated 94% of intracellular S. aureus, whereas the corresponding dose of free RPT (6.6 mg/mL) induced an 87% reduction. The in vitro results of the current study indicated that heLDL might be used as a suitable drug carrier for targeting human macrophages.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Using rifapentine – hen egg lipoprotein conjugate as macrophage-targeted drug delivery carrier against intracellularStaphylococcus aureus

Yang

Liu

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Microparticles are used as an alternative to liposomes, being more readily stable on storage or in the biological fluids, and they offer the possibility of modulation of release rate [158]. Polymers are used in different fields such as pharmaceutical, biomedicine, tissue engineering, cosmeceuticals, etc.…”

Section: Azithromycin-macrolidementioning

confidence: 99%

“…The choice of method depends on the desired size and properties of microsphere to be made, and physiochemical properties of drug [158].…”

Section: Azithromycin-macrolidementioning

confidence: 99%

“…However, these natural polymers can be modified, for instance the acylation of chitosan, to control release rate. Synthetic polymers, like poly(lactide-co-glycolide) (PLGA) copolymers, polyacrylates, poly(lactic) acid (PLA), poly(butylcyanoacrylate) and poly(lacticco-lysine) graft polymers and polyanhydrides are available and offer advantages over natural polymers as they can provide sustained/controlled release, and have high purity, homogeneity and other desirable properties [153,[156][157][158]. Targeting can also be achieved by using ligands.…”

Section: Azithromycin-macrolidementioning

confidence: 99%

See 1 more Smart Citation

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

Challenges of Drug Delivery

Wardwell

Bader

2013

Engineering Polymer Systems for Improved Drug Delivery

View full text Add to dashboard Cite

Drug delivery systems for potential treatment of intracellular bacterial infections

Cited by 81 publications

References 102 publications

Using rifapentine – hen egg lipoprotein conjugate as macrophage-targeted drug delivery carrier against intracellularStaphylococcus aureus

Using rifapentine – hen egg lipoprotein conjugate as macrophage-targeted drug delivery carrier against intracellularStaphylococcus aureus

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Challenges of Drug Delivery

Contact Info

Product

Resources

About